EMFLAZA® (deflazacort) is NOW indicated for the treatment of Duchenne muscular dystrophy in patients 2 YEARS OF AGE AND OLDER.

Understanding Duchenne

Understanding Duchenne

Duchenne muscular dystrophy is a rare disease that progressively weakens muscles over time. It's important to detect and treat Duchenne as early as possible. Treatment with corticosteroids has been shown to slow the progression of the disease.1,2

Learn more about duchenne
Treating Duchenne with Corticosteroids

Treating Duchenne with corticosteroids

Corticosteroid therapy has been shown to improve muscle strength and slow the disease progression in patients affected by Duchenne. Corticosteroids also improve the ability to accomplish tasks related to activities of daily living such as standing up, walking, and climbing stairs.1-3

Learn more about treatment with corticosteroids
Icon of delayed walking

Early intervention may help slow the progression of Duchenne

Due to the complex nature of Duchenne, intervention should happen as early as possible. Well-established guidelines confirm the benefit of corticosteroids and make recommendations on when to initiate treatment.2

1. Griggs RC, Miller JP, Greenberg CR, et al. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy. Neurology. 2016;87(20):2123-2131. 2. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9:77-93. 3. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251-267. doi:10.1016/S1474-4422(18)30024-3.